Gimeracil is a potent dihydropyrimidine dehydrogenase (DPD) inhibitor used as an adjunct in chemotherapy regimens for solid tumors to enhance the efficacy of fluoropyrimidine-based treatments. By inhibiting… Read more






























Gimeracil is a potent dihydropyrimidine dehydrogenase (DPD) inhibitor used as an adjunct in chemotherapy regimens for solid tumors to enhance the efficacy of fluoropyrimidine-based treatments. By inhibiting DPD, this agent helps maintain higher intracellular concentrations of active drugs like 5-fluorouracil. To ensure the safety and efficacy of these formulations, pharmaceutical laboratories rely on high-quality reference standards. This category provides comprehensive analytical support, including Gimeracil-related impurities, potential degradation products arising from hydrolytic or oxidative stress, and stable isotope-labeled compounds. These materials are essential for rigorous impurity profiling, precise method validation, and ongoing quality control testing. By utilizing these characterized reference standards, researchers can confidently conduct stability studies and fulfill regulatory requirements for drug development and batch release, ensuring that all analytical methods remain accurate, reliable, and compliant with established pharmacopeial standards.